POROKERATOSIS 9, MULTIPLE TYPES
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutations in the mevalonate pathway genes in Chinese patients with porokeratosis.
|
27422687 |
2016 |
POROKERATOSIS 9, MULTIPLE TYPES
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Genomic variations of the mevalonate pathway in porokeratosis.
|
26202976 |
2015 |
POROKERATOSIS 9, MULTIPLE TYPES
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Genomic variations of the mevalonate pathway in porokeratosis.
|
26202976 |
2015 |
POROKERATOSIS 9, MULTIPLE TYPES
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
POROKERATOSIS 9, MULTIPLE TYPES
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
Porokeratosis, Disseminated Superficial Actinic
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Genomic variations of the mevalonate pathway in porokeratosis.
|
26202976 |
2015 |
Porokeratosis
|
0.110 |
Biomarker
|
disease |
BEFREE |
Mutation of four genes in this pathway, including mevalonate kinase, phosphomevalonate kinase, mevalonate diphosphate decarboxylase and farnesyl diphosphate synthase, have demonstrated to be responsible for porokeratosis (PK).
|
28765912 |
2017 |
Porokeratosis
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Pruritus
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Photosensitivity of skin
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We evaluated the FDPS expression and its cancer-associated phenotypes using in vitro and in vivo methods in PTEN-deficient and sufficient human and mouse PCa cells and tumors.
|
30914801 |
2019 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting <i>Hs</i>FPPS, leading to downregulation of Ras prenylation and cell apoptosis.
|
31725297 |
2019 |
Osteoporosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
From January 2014 to March 2018, a retrospective study of 88 patients with spondylolisthesis and osteoporosis treated with minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) using the conventional pedicle screw (CPS group, n = 52) and the fenestrated pedicle screw (FPS group, n = 36) was performed with a follow-up of 30 months (range, 10-58 months).
|
31279300 |
2019 |
Osteoporosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Our study showed a strong association between bone mineral density and polymorphisms in the FDPS gene, and a borderline association with LRP5 and SOST polymorphisms in postmenopausal Romanian women with osteoporosis.No association was found for VKORC1.
|
31774873 |
2019 |
Osteoporosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
Bisphosphonates (BPs), referred to as gold standard for osteoporosis treatment, have well established role in attenuation of bone resorption and osteoclast apoptosis by inhibition of farnesyl pyrophosphate synthase enzyme (FPPS) in mevalonate pathway.
|
30096489 |
2018 |
Osteoporosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
FPS-ZM1 can rescue the negative effects of AGEs and provide a possible treatment for bone tissue regeneration in patients with diabetic osteoporosis.
|
30014569 |
2018 |
Osteoporosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
These results suggest that FDPS is important for the maintenance of glioblastoma stemness and that alendronate, a drug widely used to treat osteoporosis, can be repositioned to treat glioblastoma.
|
30333528 |
2018 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Interestingly, compared to tumor-free peripheral (TFB) brain and normal human astrocytes (NHA), FDPS protein expression and enzyme activity were detected at high degree in tumor mass where a correlation with canonical oncogenic signaling pathways such as STAT3, ERK and AKT was also documented.
|
29075041 |
2017 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
To test the combined inhibition of RAGE in both tumor cell-intrinsic and non-tumor cells of the microenvironment, we performed in vivo treatment of xenografted tumors with FPS-ZM1 (1 mg/kg, two times per week).
|
27669433 |
2017 |
Osteoporosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
|
24534219 |
2014 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
FPS-1 cells showed the same morphological and immunophenotypical characteristics as the primary tumor.
|
17094458 |
2006 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The incomplete penetrance of the neoplastic phenotype and the monoclonality of lymphoid tumors suggest that tumor formation in v-fps mice requires genetic or epigenetic events in addition to expression of the P130gag-fps protein-tyrosine kinase.
|
2555699 |
1989 |
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Experimental results revealed that VS-4 could better target the FPPS high-expressing colon LoVo and HCT116 cancer cell lines with IC<sub>50</sub> of 51.772 ± 0.473 and 43.553 ± 1.027 μM, respectively, whereas the IC<sub>50</sub> value against FPPS low expressing MDA-MB-231 cells was >100 μM.
|
31785819 |
2020 |
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Experimental results revealed that VS-4 could better target the FPPS high-expressing colon LoVo and HCT116 cancer cell lines with IC<sub>50</sub> of 51.772 ± 0.473 and 43.553 ± 1.027 μM, respectively, whereas the IC<sub>50</sub> value against FPPS low expressing MDA-MB-231 cells was >100 μM.
|
31785819 |
2020 |